Serum elastase inhibitors in cardio-vascular diseases.
Serum elastase inhibiting capacity was measured in three groups: 150 control subjects, 38 hospitalized children without cardiovacular diseases and 202 hospitalized patients suffering from cardiovascular diseases. The values obtained were 53% in control adult subjects and 79% (range 45--90%) in the hospitalized patient groups. The highest levels were recorded at the acute phase of myocardial infarction. The levels of alpha 1-antitrypsin (alpha1-AT) and alpha 2-macroglobulin (alpha2-M) were determined by radial immunodiffusion technique for various levels of inhibitory power. No correlation was found between the inhibitory power levels and the alpha1-AT and alpha2-M levels. This study suggests that other proteins may intervene in the inhibition process of elastolysis.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D002318:Cardiovascular Diseases / Q000097:blood*; D002648:Child; D004791:Enzyme Inhibitors / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood; D010196:Pancreatic Elastase / Q000037:antagonists & inhibitors*; D000515:alpha 1-Antitrypsin / Q000378:metabolism; D000511:alpha-Macroglobulins / Q000378:metabolism
D004791:Enzyme Inhibitors; D000515:alpha 1-Antitrypsin; D000511:alpha-Macroglobulins; D010196:Pancreatic Elastase